Physician profile
Jose Avitia
NPI 1669511663
$11,490.60
in general payments reported to CMS, 2019-2025
31 companies · $4,189 in 2025
The $4,189 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $2,326 · 2021: $2,681 · 2022: $273 · 2023: $1,269 · 2024: $435 · 2025: $4,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,714 · Food and Beverage: $956 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,713.75 |
| Food and Beverage | $956.32 |
| Education | $223.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $3,639.00 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $1,694.47 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,676.61 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $1,200.00 | 2020 | |
| Janssen Scientific Affairs, LLC | $953.75 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $550.00 | 2025 | |
| Astellas Pharma US INC | $463.28 | 2021-2025 | Xtandi |
| Pfizer INC. | $171.09 | 2019-2024 | |
| Asd Specialty Healthcare, LLC | $144.31 | 2019-2025 | |
| Abbvie INC. | $139.19 | 2019-2025 | Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $134.40 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $129.35 | 2019-2024 | Keytruda, Welireg |
| Lilly USA, LLC | $83.33 | 2022 | |
| Genentech USA, INC. | $65.00 | 2019 | |
| Janssen Biotech, INC. | $64.81 | 2023-2024 | Erleada, Balversa, Akeega |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $53.55 | 2020-2023 | Xpovio |
| Exelixis INC. | $32.27 | 2019 | |
| Genzyme Corporation | $30.50 | 2024 | |
| Aveo Pharmaceuticals, INC. | $27.83 | 2022 | |
| Beigene USA, INC. | $27.16 | 2024 | Brukinsa |
| Genmab U.S., INC. | $26.75 | 2024 | Epkinly |
| Seagen INC. | $26.22 | 2022 | |
| G1 Therapeutics, INC. | $24.06 | 2023 | Cosela |
| Celgene Corporation | $22.11 | 2024 | Reblozyl |
| Epizyme, INC. | $19.45 | 2021 | |
| Coherus Oncology, INC. | $19.41 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Taiho Oncology, INC. | $16.83 | 2020 | |
| Axonics, INC. | $13.52 | 2022 | |
| Mirati Therapeutics, INC. | $13.41 | 2024 | Krazati |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Avitia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.